Researchers at the Mayo Clinic have discovered that the body’s cancer-fighting CD8-positive T cells begin preparing for their immune role much earlier than previously believed. Instead of developing these abilities only after leaving the thymus, the cells start this process while still maturing inside the thymus.
The study also found that the PD-1 protein acts as an important brake during early T-cell development, helping prevent the cells from becoming exhausted too quickly. In preclinical studies, removing PD-1 improved early tumor control but caused the T cells to wear out faster, reducing their long-term effectiveness.
The findings suggest that future immunotherapies should balance strong anti-cancer activity with preserving T-cell endurance for lasting benefits.
In the same study, researchers also revealed the first detailed molecular structure of PKCĪ², showing how the breast cancer drug endoxifen interacts with the protein. These findings are based on laboratory and preclinical research and require further study before being applied to patient care.